Gossamer Bio Q2 FY26 returns to profit at $16.9 million; revenue falls 19.6% to $9.24 million
GOSS•Q2 returns to profit as revenue declines
Gossamer Bio posted Q2 net income of USD 16.9 million, swinging from a net loss a year earlier.
Revenue fell 19.59% to USD 9.24 million, reflecting collaboration revenue tied to Chiesi.
Expenses fall and seralutinib timeline remains on track
R&D expenses dropped 36.48% to USD 26.41 million on lower clinical-trial costs for seralutinib.
Cash, cash equivalents and marketable securities totaled USD 57.03 million at June 30, with funding expected into Q1 2027.
Pre-NDA Type B minutes keep a seralutinib PAH NDA on track for September 2026; worldwide rights were reacquired from Chiesi.
